EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical outcomes in transplant‐eligible patients with relapsed or refractory diffuse large B‐cell lymphoma after second‐line salvage chemotherapy: A retrospective study

Yu Yagi, Yusuke Kanemasa iD, Yuki Sasaki, Mina Sei, Takuma Matsuo, Kento Ishimine, Yudai Hayashi, Mano Mino, An Ohigashi, Yuka Morita, Taichi Tamura, Shohei Nakamura und 11 weitere

Cancer Medicine · 2023

DOI: 10.1002/cam4.6412 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Yu Yagi und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Salvage Therapy, Antineoplastic Combined Chemotherapy Protocols, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The prognosis of patients with relapsed or refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) is poor. Although patients who fail first‐line salvage chemotherapy are candidates for second‐line salvage chemotherapy, the optimal treatment strategy for these patients has not yet been established.

Methods

The present, single‐center, retrospective study included transplant‐eligible patients with R/R DLBCL who received second‐line salvage chemotherapy with curative intent.

Results

Seventy‐six patients with R/R DLBCL received second‐line salvage chemotherapy. Eighteen (23.7%) patients were responders to the first‐line salvage chemotherapy. The overall response rate was 39.5%, and overall survival (OS) was significantly longer in patients who responded to second‐line salvage chemotherapy than those who did not. Forty‐one patients who proceeded to potentially curative treatment (autologous hematopoietic stem cell transplantation [ASCT], chimeric antigen receptor [CAR] T‐cell therapy, or allogeneic hematopoietic stem cell transplantation) had a better prognosis than those who did not. Among the 46 patients who failed to respond to the second‐line salvage regimen, only 18 (39.1%) could proceed to the curative treatments. However, among the 30 patients who responded to the second‐line salvage regimen, 23 (76.7%) received one of the potentially curative treatments. Among 34 patients who received CAR T‐cell therapy, OS was significantly longer in those who responded to salvage chemotherapy immediately prior to CAR T‐cell therapy than in those who did not respond. In contrast, the number of prior lines of chemotherapy was not identified as a statistically significant prognostic factor of survival. No significant difference was detected in OS between patients receiving ASCT and those receiving CAR T‐cell therapy after the response to second‐line salvage chemotherapy.

Discussion

In this study, we demonstrated that chemosensitivity remained a crucial factor in predicting survival outcomes following CAR T‐cell therapy irrespective of the administration timing, and that both ASCT and CAR T‐cell therapy were acceptable after the response to second‐line salvage chemotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseSalvage TherapyAntineoplastic Combined Chemotherapy ProtocolsNeoplasm Recurrence, LocalHumansMaleFemaleMiddle AgedRetrospective StudiesAdultAgedHematopoietic Stem Cell TransplantationTreatment OutcomePrognosisYoung AdultImmunotherapy, Adoptive

Stichwörter der Autor:innen

autologous stem cell transplantationchimeric antigen receptor T-cell therapyrelapsed or refractory diffuse large B-cell lymphomasalvage chemotherapy

Autor:innen und Institutionen

  • Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
  • Department of Pharmacy, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
  • Department of Radiation Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
  • Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
  • Division of Transfusion and Cell Therapy, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.

ORCID-Profile: Yusuke Kanemasa, Yuho Najima

Zitieren

APA

Yagi, Y., Kanemasa, Y., Sasaki, Y., Sei, M., Matsuo, T., Ishimine, K., Hayashi, Y., Mino, M., Ohigashi, A., Morita, Y., Tamura, T., Nakamura, S., Okuya, T., Shimizuguchi, T., Shingai, N., Toya, T., Shimizu, H., Najima, Y., Kobayashi, T., …, & Shimoyama, T. (2023). Clinical outcomes in transplant‐eligible patients with relapsed or refractory diffuse large B‐cell lymphoma after second‐line salvage chemotherapy: A retrospective study. Cancer Medicine. https://doi.org/10.1002/cam4.6412

Vancouver

Yagi Y, Kanemasa Y, Sasaki Y, Sei M, Matsuo T, Ishimine K, et al. Clinical outcomes in transplant‐eligible patients with relapsed or refractory diffuse large B‐cell lymphoma after second‐line salvage chemotherapy: A retrospective study. Cancer Medicine. 2023. doi:10.1002/cam4.6412

BibTeX
@article{Yagi2023,
  author = {Yagi, Yu and Kanemasa, Yusuke and Sasaki, Yuki and Sei, Mina and Matsuo, Takuma and Ishimine, Kento and Hayashi, Yudai and Mino, Mano and Ohigashi, An and Morita, Yuka and Tamura, Taichi and Nakamura, Shohei and Okuya, Toshihiro and Shimizuguchi, Takuya and Shingai, Naoki and Toya, Takashi and Shimizu, Hiroaki and Najima, Yuho and Kobayashi, Takeshi and Haraguchi, Kyoko and Doki, Noriko and Okuyama, Yoshiki and Shimoyama, Tatsu},
  title = {Clinical outcomes in transplant‐eligible patients with relapsed or refractory diffuse large B‐cell lymphoma after second‐line salvage chemotherapy: A retrospective study},
  journal = {Cancer Medicine},
  year = {2023},
  doi = {10.1002/cam4.6412}
}
Kostenlos starten →